Medical Innovation Exchange

Merck KGaA, with phase 3 data on the horizon, showcases durability of evobrutinib in multiple sclerosis

https://www.fiercebiotech.com/biotech/merck-kgaa-phase-3-data-horizon-showcases-durability-evobrutinib-multiple-sclerosis

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!